THU0620 PERSISTENCE WITH BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS -A RETROSPECTIVE DATABASE STUDY IN JAPANESE PATIENTS WITH RHEUMATOID ARTHRITIS
Background: Persistence rate is one of the key benefits of biological diseasemodifying antirheumatic drugs (bDMARDs) in the treatment of rheumatoid arthritis (RA). Limited evidence of persistence has been found in Japan and the results are not transferrable across countries and cultures (1-3). In addition, the impact of persistence on healthcare cost is still questionable. Objectives: To assess persistence rates of bDMARDs for the treatment of RA in Japan and compared resource utilization and treatment costs between persistence and non-persistence groups. Methods: Data was extracted from a Japanese claims database that included 4,400,000 patients between 2009 and 2015. RA patients who initiated bDMARD treatment (bDMARD-naïve patients) were identified and included in the final analysis. Survival analysis was used to estimated 6-, 12-, and 18-month persistence rates for current bDMARDs. Propensity score matching was applied to control for potential treatment selection bias. Resource utilization and health care costs of treatments were calculated 12 months before and after initiation of bDMARDs treatment and compared between persistence and non-persistence groups.
Results: A total of 6,153 bDMARD-naïve patients were included in the final analysis. The overall 1-year persistence rate was 85% (95% CI, 84-86).
Persistence of patients treated with golimumab was higher [92% (95% CI, 89-94)] than that with other bDMARDs. Overall, 1-year outpatient visits increased from 10 at baseline to 16 after bDMARD treatment, while the number of hospital admissions declined from 3.3 to 1.6. Hospital days decreased from 17 at baseline to 12 following treatment. The non-persistence group had a larger increase in outpatient visits after bDMARD initiation compared with the persistence group (8 to 16 vs. 10 to 16, respectively) and a smaller decrease in hospital admissions (3.1 to 1.9 vs. 3.5 to 1.4, respectively). Compared to non-persistence group, persistence was associated with a reduction in total healthcare costs of 760 USD. Conclusions: Japanese bDMARD-naïve patients with RA have a high persistence rate of bDMARDs. The reduction in medication costs in non-persistent patients is offset by higher hospitalization costs, making non-persistence more expensive. 
Objectives:
To compare the effect of anti-TNF therapy (a-TNF-th) on Work Disability (WD) between RA, PSA and AS. In the Czech Republic (CZ), a-TNF-th is reimbursed for RA if DAS28>5.1 despite therapy with csDMARDs, for PSA if disease is not "adequately controlled" with csDMARDs, and for AS if BASDAI>4 and CRP/ESR elevated above normal. More than 95% of anti-TNF treated patients in CZ are followed up in the ATTRA registry. Methods: Bionäive patients with RA (n=1085), AS (n=1126) and PSA (n=351) starting a-TNF-th with available baseline data on demography, disease duration and physical function, and on working status at baseline and at 12 months were included in the analysis. Patients older than 60 years, on maternity leave or students were excluded. Work status was self-reported by patients as (A) able to work = [(i) employed, or (ii) unemployed and actively seeking employment], or (B) unable to work = [(iii) on sick leave, or (iv) on disability pension]. Regression analyses were performed to examine the predictors of improvement in WD (change B→A coded as 1, B→A as -1, no change as 0) over 1 year. 
